CURRENT ISSUE

Genetic Engineering " Biotechnology News - Current Issue

(view larger image)

SUBSCRIBE

AD LINK

Visit GEN on Twitter!

GEN News Highlights

  • Print
  • Share
  • More GEN News Highlights

Mar 7 2007, 12:09 PM EST

Aeras Commits $5M to Crucell for Continued TB Research

GEN News Highlights

Crucell will receive up to $5 million from Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine.

"This technology, which is based on one of the most advanced vector delivery systems for induction of cellular immunity, represents an important part of the portfolio of vaccines we are developing against tuberculosis," states Jerald C. Sadoff, president & CEO of Aeras Global TB Vaccine Foundation.

In March 2004, Aeras and Crucell entered into a collaborative agreement for the development of a PER.C6® and AdVac®-based TB vaccine. The vaccine entered a Phase I trial in October 2006.

  • Print
  • Share
  • More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:

HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

Visit the GEN Career Center

for the latest biotech employment opportunities.
Start your search HERE!

visit the Career Center

WEBINARS

view all webinars

GEN and Scintellix bring you the Cryptogram Challenge: RNAi!

PODCASTS

INTERVIEW: NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates ...MORE

MOST POPULAR

News

Articles

Blogs